Bloodgene Bio closes B2, total Series B nears US$41.3M
What's the deal? Bloodgene Bio (血霁生物), a Chinese stem cell therapy and drug development company, has closed the second tranche of its Series B round, raising over US$13.8M (roughly $14M). The B2 close brings the total Series B to nearly US$41.3M (around $41M).
The company had announced its B1 tranche — also over US$13.8M — just four months earlier. The B2 round drew new investors Shenzhen Capital Group and Hebei Industrial InvestmentDealroom has a profile for this one. Try Dealroom →, alongside existing backers DH CapitalDealroom has a profile for this one. Try Dealroom → (鼎晖投资), Weidu Ventures (苇渡创投), and others.
Why now? Bloodgene Bio specialises in directing stem cells to regenerate blood cells for use in cell therapies and related drug development. The field of stem cell-derived blood products is gaining momentum globally as researchers seek alternatives to traditional blood transfusions and new treatments for blood disorders.
Closing two tranches within four months suggests strong investor appetite and steady progress on the company's development milestones.
What could go wrong? Cell therapy remains a long, capital-intensive road from lab to clinic. Regulatory approval timelines in China — and internationally, if the company expands — are uncertain. Competition from other stem cell and cell therapy players is intensifying, and the company will likely need additional funding rounds before reaching commercialisation.
The signal: The participation of state-backed investment funds Shenzhen Capital Group and Hebei Industrial Investment alongside established venture backers like DH Capital underscores how Chinese government-linked capital is actively channelling into advanced cell therapy as a strategic sector — even as broader biotech funding tightens. Bloodgene Bio's ability to close two tranches totalling nearly US$41.3M within roughly four months points to unusually strong conviction around stem cell-derived blood products as a near-term clinical opportunity.
Read more: ITjuzi
